期刊文献+

基因组学——未来医药学的方向 被引量:2

Genomics——The Direction of the Future Medicine
在线阅读 下载PDF
导出
摘要 目的:综述基因组学在未来医药学领域的作用及个体化医疗的发展方向。方法 :分析评述近年来国内外相关文献资料。结果 :在基因组学时代,医师和药师可以在分子水平上预测疾病,诊断疾病,判断疾病进展和预后以及利用药物基因组学的知识进行药物治疗。结论 :医学模式将从以往的"检查和治疗疾病"转向"预测和预防疾病"。医药学将更安全,有效,具有特异性,从而实现个体化医疗,真正做到以人为本。 Objective: To review the effect of genomics in the medicine domain and development direction of individualized medicine. Methods: Analysis and give comments on literature at home and abroad in recent years. Results: On the genomics times, doctors and pharmacists could be able to predict and diagnose diseases, judge the progress and prognosis, and prescribe drugs basing on the pharmacogenomics. Conclusions: The mode of the medicine would change from "examine and cure diseases" to "predict and prevent diseases" . Medicine would be safer, more effective and specific. "Individualized medicine" " would come, and it is really human-oriented.
出处 《药品评价》 CAS 2010年第10期2-5,共4页 Drug Evaluation
基金 首都医科大学基础-临床科研合作基金(2007JL40)
关键词 基因组学 药物基因组学 个体化治疗 Genomics Pharmacogenomics Individualized medicine
作者简介 任夏洋,女,项士研究生,研究方向:临床药学。电话:010-67096862;Email:erxia10@163.com 通讯作者:赵志刚,男,主任药师,硕士生导师,主要从事医院药学管理和临床药学研究。Tel:(010)67098036;E-mail:1022ZZS@sra.com
  • 相关文献

参考文献7

二级参考文献59

  • 1许力,王升启.药物基因组学的发展及其在个体化用药中的应用[J].国外医学(药学分册),2006,33(6):441-444. 被引量:22
  • 2李金恒.临床个体化用药中的药物基因组学考虑[J].中国临床药理学与治疗学,2007,12(4):361-365. 被引量:17
  • 3Siest G, Jeannesson E, Berrahmoune H, et al. Phamacogenomics and response in cardiovascular disorders [ J ]. Phamacogenomics, 2004,5(7) :779-802.
  • 4Destenaves B, Thomas F. New advances in phamacogenomics [ J ]. Curr Opin Chem Biol,2000,4(4) :440-444.
  • 5Bailey D S, Bondal A, Fumess L M. Phamacogenomics-it's not just phamacogentics [ J ]. Curr Opin Biotechnol, 1998,9 ( 6 ) : 595-601.
  • 6Romkes M, Buch S C. Genotyping teshnologies; application to biotransformation enzyme genetic polymorphism screeing[ J]. Methods Mol Biol,2005 ,291:399-414.
  • 7Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2CI9 pharmacogenetic polymorphism on proton pump inhibitorbased therapies[ J]. Drug Metab Pharmacokinet. 2005,20(3 ) :153-167.
  • 8Mcleod H L,Krynetski E Y,Relling M V,et al. Genetic Polymorphism of thiopurine methyhransferase and its clinical releance for childhood acute lymphoblastic leukemia [ J ]. Leukem ia, 2000, 14:567 -572.
  • 9Krynetski E Y, Evans W E. Pharmacogenetics as a molecular basis for individulized drug therapy: the thiopurine smethyltransferase paradigm [ J ]. Pharm Res, 1999,16 ( 3 ) :342-349.
  • 10Hu YF,He J,Chen GL,et al.CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population[J].Clin Chim Acta,2005,353(1-2):187-92.

共引文献37

同被引文献49

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部